Lv1
30 积分 2025-02-01 加入
Antibody-drug conjugates: A review of cutaneous adverse effects
3个月前
已完结
Retinal ischemia: mechanisms of damage and potential therapeutic strategies
3个月前
已完结
Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization
3个月前
已完结
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
9个月前
已完结
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
9个月前
已完结
Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer
10个月前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
1年前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
1年前
已完结
BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization
1年前
已完结
皖公网安备34019202002308
